York Pharma acquires Molecular SkinCare

York Pharma, the UK-based acquirer, developer and marketer of pharmaceutical products in the field of dermatology, has acquired Sheffield-based Molecular SkinCare, which develops novel dermatology products for the prevention and management of skin diseases.

The acquisition expands York Pharma's product portfolio into the key dermatology therapeutic markets of eczema and psoriasis, and gives it an international patent portfolio consisting of six wholly owned published patent families including patent applications and associated know-how to treat and prevent atopic eczema and psoriasis. The company also acquires laboratory, complementary development and clinical dermatology expertise.

Founded in 2001, Molecular SkinCare emerged from the University of Sheffield with expertise in the field of functional genomics, molecular biology and clinical dermatology. There are four projects in its portfolio which operate principally in the markets of atopic eczema and psoriasis. These dermatological projects are expected to reach important development and clinical milestones in 2005 and 2006.

One of the products which Molecular SkinCare will bring to York Pharma is currently under development for the treatment of psoriasis. Plans to commence a phase IIa clinical trial in 2005 are underway, with in vitro and in vivo data suggesting that the compound has the potential to address many of the shortcomings of the existing gold-standard vitamin D analogue therapies.

In addition, York Pharma will acquire platform technology relating to the repair of the skin barrier (SBR Technology). Damage to the skin barrier is thought to allow the ingress of allergens, which sets in train a cascade which initially triggers eczema. The first product arising from this platform technology will be developed as a cream formulation for eczema and will commence human clinical efficacy studies in 2005.

"This is a business transforming transaction, which both parties recognised as a perfect fit," said Terry Sadler, York Pharma ceo. "The quality of the combined portfolio and enlarged team creates a business that will make a significant impact on the dermatology market in the coming years, both scientifically and commercially."

Michael Garrison, currently ceo of Molecular SkinCare, joins the board of York Pharma as commercial director.